Genomed (WAR:GEN) Beneish M-Score: -1.62 (As of Jun. 26, 2026)


WAR:GEN Genomed SA WAR:GEN
75 GF Score
Price zł25.80
GF Value zł37.76
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed Beneish M-Score?

Genomed WAR:GEN -2.27% 75 Beneish M-Score is -1.62 as of Jun. 26, 2026. GuruFocus rates WAR:GEN with a GF Score™ of 75/100 and a GF Value™ of zł37.76 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Genomed ranks worse than 85.13% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.62 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Genomed's Beneish M-Score or its related term are showing as below:

WAR:GEN' s Beneish M-Score Range Over the Past 10 Years
Min: -5.71   Med: -2.18   Max: -0.51
Current: -1.62

During the past 13 years, the highest Beneish M-Score of Genomed was -0.51. The lowest was -5.71. And the median was -2.18.


Genomed Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Genomed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Beneish M-Score Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.27 -1.33 -2.82 -2.83 -1.62

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.62 0.00

WAR:GEN vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Genomed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomed Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Genomed's Beneish M-Score falls into.


WAR:GEN
75GF Score
Genomed SA WAR:GEN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Genomed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4646+0.528 * 0.9494+0.404 * 1.4521+0.892 * 1.2658+0.115 * 1.229
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.010045-0.327 * 1.1025
=-1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was zł3.36 Mil.
Revenue was zł29.12 Mil.
Gross Profit was zł19.33 Mil.
Total Current Assets was zł11.61 Mil.
Total Assets was zł16.53 Mil.
Property, Plant and Equipment(Net PPE) was zł2.84 Mil.
Depreciation, Depletion and Amortization(DDA) was zł0.76 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.00 Mil.
Total Current Liabilities was zł2.29 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.00 Mil.
Net Income was zł3.40 Mil.
Gross Profit was zł0.00 Mil.
Cash Flow from Operations was zł3.23 Mil.
Total Receivables was zł1.81 Mil.
Revenue was zł23.01 Mil.
Gross Profit was zł14.50 Mil.
Total Current Assets was zł9.19 Mil.
Total Assets was zł12.40 Mil.
Property, Plant and Equipment(Net PPE) was zł2.13 Mil.
Depreciation, Depletion and Amortization(DDA) was zł0.74 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.00 Mil.
Total Current Liabilities was zł1.56 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.361 / 29.122) / (1.813 / 23.007)
=0.115411 / 0.078802
=1.4646

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(14.495 / 23.007) / (19.326 / 29.122)
=0.630026 / 0.663622
=0.9494

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.611 + 2.842) / 16.526) / (1 - (9.193 + 2.134) / 12.398)
=0.125439 / 0.086385
=1.4521

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=29.122 / 23.007
=1.2658

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.744 / (0.744 + 2.134)) / (0.757 / (0.757 + 2.842))
=0.258513 / 0.210336
=1.229

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 29.122) / (0 / 23.007)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 2.294) / 16.526) / ((0 + 1.561) / 12.398)
=0.138812 / 0.125907
=1.1025

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3.4 - 0 - 3.234) / 16.526
=0.010045

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Genomed has a M-score of -1.62 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.62 mean?
Genomed (WAR:GEN) has a Beneish M-Score of -1.62 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Genomed and its competitors. According to the industry distribution chart, Genomed ranks #166 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 85.1%.
Is Genomed's Beneish M-Score too high?
Genomed's current Beneish M-Score is -1.62. Based on the distribution chart, Genomed ranks #166 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genomed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genomed ranks #166 out of 195 companies for Beneish M-Score. This places Genomed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Genomed and its competitors. Genomed's current Beneish M-Score is -1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Significantly Undervalued. The stock's GF Value™ is zł37.76, compared to a current price of zł25.80 — trading 31.7% below its estimated fair value. The current Beneish M-Score is -1.62. Genomed's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Beneish M-Score is -1.62 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł25.80 is trading 31.7% below its estimated GF Value™ of zł37.76. GuruFocus considers Genomed to be Significantly Undervalued.

Key valuation signals for WAR:GEN:

  • Beneish M-Score: -1.62
  • GF Value™: zł37.76 vs. price of zł25.80 (31.7% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
75GF Score

Get the complete analysis for WAR:GEN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł25.80
Price
zł37.76
GF Value